Moderate aerobic exercise and probiotic intake on FOXA1 gene expression in non-alcoholic fatty liver animal model: An Experimental Study
Subject Areas : Sport Physiology
Shahin Riyahi Malayeri
1
*
,
Hamzeh MohamMadi Firooz Abad
2
,
Omid Soleimani Ghaleh
3
,
Soheila Azarkhosh
4
1 - Department of Physical Education and Sport Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.
2 - MSc in Exercise Physiology, Sport Nutrition.
3 - MSc in Exercise Physiology, Sport Nutrition.
4 - MSc in Exercise Physiology, Sport Nutrition.
Keywords: Aerobic exercise, FOXA1, non-alcoholic fatty liver, probiotics,
Abstract :
Background: Fatty liver disease is also known as fatty liver syndrome and is also called hepatic steatosis the aim of this study was to evaluate the effect of eight weeks of aerobic exercise and probiotic intake on FOXA1 gene expression in rats with fatty liver. Methods: This study is an experimental laboratory study. Thirty-two male wistar rats were divided into 4 groups of 8 in the healthy, steatosis, steatosis + probiotic, steatosis + probiotic +aerobic exercise groups and tested for 8 weeks. The exercise protocol was as follows: in the first week from 10 minutes of running at a speed of 18 meters per minute to the eighth week with 60 minutes of running at a speed of 28 meters per minute. Consumption of probiotics; Relevant groups received 109 CFU / ml of Lactobacillus rhamnosus GG by gavage daily for 5 weeks and 5 days a week. RT-pcr method was used to evaluate the expression of FOXA1gene. ANOVA were used for data analysis using SPSS 23 software at a significant level (p <0.05). Results: The results showed that eight weeks of aerobic exercise with probiotic intake had a significant decrease on the expression of FOXA1 gene and LDL in rats with fatty liver (P <0.05). Conclusion: According to the results of the study, It seems that aerobic exercise with probiotics intake can improve the liver function of non-alcoholic fatty liver patients.
1- Alves-Bezerra M, Cohen DE. Triglyceride Metabolism in the Liver. Compr Physiol. 2017 Dec 12;8(1):1-8. doi: 10.1002/cphy.c170012. PMID: 29357123; PMCID: PMC6376873.
2- Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol. 2015 Apr 28;7(6):846-58. doi: 10.4254/wjh. v7. i6.846. PMID: 25937862; PMCID: PMC4411527.
3- Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev. 2008 Dec;29(7):777-822. doi: 10.1210/er.2008-0024. Epub 2008 Oct 29. PMID: 18971485; PMCID: PMC5393149.
4- Friedman JR, Kaestner KH. The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci. 2006 Oct;63(19-20):2317-28. doi: 10.1007/s00018-006-6095-6. PMID: 16909212.
5- Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J. 2011 Sep 20;30(19):3885-94. doi: 10.1038/emboj.2011.340. PMID: 21934649; PMCID: PMC3209791.
6- Moya M, Benet M, Guzmán C, Tolosa L, García-Monzón C, Pareja E, Castell JV, Jover R. Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver. PLoS One. 2012;7(1):e30014. doi: 10.1371/journal.pone.0030014. Epub 2012 Jan 6. PMID: 22238690; PMCID: PMC3253125.
7- Qiu, M., Bao, W., Wang, J. et al. FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer. BMC Cancer 14, 78 2014. https://doi.org/10.1186/1471-2407-14-78
8- Zhao Y, Li Z. Interplay of estrogen receptors and FOXA factors in the liver cancer. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3(0 3):334-9. doi: 10.1016/j.mce.2015.01.043. Epub 2015 Feb 4. PMID: 25661537; PMCID: PMC4524798.
9- Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017 Sep 15;9(9):1021. doi: 10.3390/nu9091021. PMID: 28914794; PMCID: PMC5622781.
10- Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013 Jan;6(1):39-51. doi: 10.1177/1756283X12459294. PMID: 23320049; PMCID: PMC3539293.
11- Mohammadi, S., Rostamkhani, F., Riyahi Malayeri, S. et al. High-intensity interval training with probiotic supplementation decreases gene expression of NF-κβ and CXCL2 in small intestine of rats with steatosis. Sport Sci Health 2021. https://doi.org/10.1007/s11332-021-00829-5.
12- Hedayati S, Riyahi Malayeri S, Hoseini M. The Effect of Eight Weeks of High and Moderate Intensity Interval Training Along with Aloe Vera Consumption on Serum Levels of Chemerin, Glucose and Insulin in Streptozotocin-induced Diabetic Rats: An Experimental Study. JRUMS. 2018; 17 (9) :801-814. URL: http://journal.rums.ac.ir/article-1-4209-fa.html
13- Sturgeon KM, Schweitzer A, Leonard JJ, Tobias DK, Liu Y, Cespedes Feliciano E, Malik VS, Joshi A, Rosner B, De Jonghe BC. Physical activity induced protection against breast cancer risk associated with delayed parity. Physiol Behav. 2017 Feb 1;169:52-58. doi: 10.1016/j.physbeh.2016.11.026. Epub 2016 Nov 21. PMID: 27884590; PMCID: PMC6913777.
14- Khalifa, O., AL-Akl, N.S., Errafii, K. et al. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Sci Rep 12, 2226 2022. https://doi.org/10.1038/s41598-022-06143-5
15- Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014 Feb;44(2):211-21. doi: 10.1007/s40279-013-0110-5. PMID: 24174305; PMCID: PMC3906547.
16- Shirpoor M, Tofighi A, Shirpoor A, Pourjabali M, Chodari L. Effect of moderate exercises and curcumin on hepatic transcriptional factors associated with lipid metabolism and steatosis in elderly male rat. Res Pharm Sci. 2021 May 12;16(3):294-304. doi: 10.4103/1735-5362.314828. PMID: 34221063; PMCID: PMC8216158.
17- Kazeminasab F, Marandi M, Ghaedi K, Esfarjani F, Moshtaghian J. Effects of A 4-Week Aerobic Exercise on Lipid Profile and Expression of LXRα in Rat Liver. Cell J. 2017 Apr-Jun;19(1):45-49. doi: 10.22074/cellj.2016.4871. Epub 2016 Dec 21. PMID: 28367416; PMCID: PMC5241517.
18- Xie C, Halegoua-DeMarzio D. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? Nutrients. 2019 Nov 19;11(11):2837. doi: 10.3390/nu11112837. PMID: 31752378; PMCID: PMC6893593.
19- Duseja A, Acharya SK, Mehta M, Chhabra S; Shalimar, Rana S, Das A, Dattagupta S, Dhiman RK, Chawla YK. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 2019 Aug 7;6(1):e000315. doi: 10.1136/bmjgast-2019-000315. PMID: 31423319; PMCID: PMC6688701.